Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Becton Dickinson develops and manufactures medical devices, laboratory equipment, and diagnostic products across a broad portfolio spanning medication management, surgical products, and diagnostic testing, currently working through a planned separation of certain business segments.
Business model
The company earns revenue from selling medical devices and diagnostic products to hospitals and healthcare providers globally, with recurring consumables revenue tied to its large installed device base supplementing new equipment sales.
Growth drivers
- Medication management technology adoption
- Diagnostics testing volume growth
- Portfolio separation potentially unlocking segment specific value
- International market expansion
Competitive position
Becton Dickinson's broad device and diagnostics portfolio gives it exposure across many medical categories, though the company has faced execution challenges in certain segments that its planned portfolio separation aims to address.
Risks
Portfolio separation execution carries transaction and operational complexity risk, competition in medical devices and diagnostics is intense, and healthcare capital spending cycles affect hospital purchasing.
Valuation
Becton Dickinson trades at a moderate multiple typical of diversified medical device companies, with the market anticipating potential value creation from its planned separation into more focused business units.
Final view
Becton Dickinson's planned portfolio separation could unlock value if focused business units achieve improved execution and valuation. My view is cautiously favorable, with separation execution progress being the key thing to track.
Overall rating: 65/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.